Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study for HSK47388 in Participants With Ulcerative Colitis
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Summary
The purpose of this protocol is to evaluate the efficacy and safety of HSK47388 as therapy in participants with moderately to severely active ulcerative colitis .
Official title: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of HSK47388 in Participants With Moderately to Severely Active Ulcerative Colitis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2026-02-03
Completion Date
2029-02-02
Last Updated
2026-03-05
Healthy Volunteers
No
Conditions
Interventions
HSK47388
Participants will be randomized to receive HSK47388, orally starting at Week 0 . At Week-12, all participants will be evaluated for clinical response and responders will enter the maintenance study.
Placebo
Participants will be randomized to receive Placebo, orally starting at Week 0 . At Week-12, all participants will be evaluated for clinical response and responders will enter the maintenance study.
Locations (1)
Sir Run Run Shaw Hospital
Hangzhou, China